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Basrl. Swirrerland 
n&e investigated pmspeclively in pafiat& with persistiig 
asymptanattc anptex arrhythmias oner myocardiat in- 
farction. Eod points were total mortality and arrhytbmir 
evell,s (suddo” d&b, ws,ai”ed “a”,r*“lsr Lacbycardia 
and vsn,rictdar fibrillation). 
Oi1,27.Qccmwulivelyscreened wvivorsofmyocardial 
bUmT,bx,, 312 bad Lown class 3 or Ib arrbylbmia on 24 h 
eledmcardiograpbii rmmiings before bmpilal discharge 
and come”,ed ,a ,lle study. They were randomized to 
Miv,d”sdized Pnlisrrbyibmie ,Tea,men, Group 1, ” = 
IW), hearmpn, with low dose amicxtamne, 200 mg/day 
Comp!ex ventricular arrhythmias penisting after myocardial 
infarction have been identified as a predictor of mortality 
(l-3) independent of and additive to the prognostic value of 
left vent&ular ejection fraction (4.5). However. to date. 
antiarrhvthmic drue trials (6-9) have not demonstrated B 
reduction in mortally: in fact. an excess mortality has been 
rewrted (IO) in patients treated with class Ic antiarrhvthmic 
d&s. Earlier &dies of antiarrhyrhmic agents have been 
criticized on several grounds: fixed dosage. single antiar- 
rhythmic drug and no serum drug level measurernenb. 
However, an individualized approach to optimize :berapy 
could bc important for the success of antiarrhythmic dw 
therapy. Alternatively. a simple regimen favoring good com- 
plrance and tolerance based on once daily application of a 
Ions_acting drug might reduce the high dropout rate ob- 
s&d in previ& &dies (9). 
We designed a pm~pecttve randomized tnal in patents at 
high risk after myocardial infarction: only patients with 
complex ventricular ectopic activity persisting up to hospiral 
discharge were entered-into the study. They were then 
randomly allocated to one of three treatment regimens: 1) 
individualized antiarrhythmic treatment. startin% with 
clars I agents selected on the basis of suppression of 
ventricular rctapic activity and patient tolennce: 2) wan- 
dardized antmrrhythmic treatment with low dose amio- 
&row. a drug with a long half-life (I I): and 3) na anti=- 
rhythmic therapy (control group). Over a I year follow-up 
period. clinsal events, antianhythmic drug effects and side 
effects were worded to assess s!lether one or both of the 
chow, ant+hvlhmir dn? @m**s $ven pr@phylxticJ!y 
cuuld r+w m&a!ity. 
y.._L.. 
Pe.tient sel&. All patients <?I years of age consecu- 
tively admttted to the coronary care unit of the Universl!y 
Hospitel of Beset with acute mywardial infarction between 
Joly !, 1981 and June 30, 1967 were considered for this 
study. leczur~ F. planned interim analysis after 2.5 years of 
oatient recroitment showed that the incidence of complex 
;enhicular arrhythmias as defined in this study was lower 
than predicted. the study was extended to two afflialed 
hos&ls (ffintonsspit;ile~ Bruderholz and Liesml) to obtain 
adequate patient numbers. 
Before hospitai dkharge. l,?Zf patients were screened 
for persistent complex ventticulrr ectopic arrhythmias. 
Death in the hospital, symptomatic: arrhythmias or cardio- 
vascular surgery &ring ho~pitalizt.tion. life-threatening CD 
morbidity and unavailability for tallow-up evaluation were 
reasons for primary exclusion. Only patients who showed 
asymptomatic omplex ventricular ectopic activity on a 24 h 
electrocardiographic (ECG) recording before hospital dis- 
charge were included in the rtudy. Each patient received a 
consecutive number based on the time of entry into the 
hospital that WBP later used for randomization. which was 
performed separately for the three hospitals. 
Study protwoi. All patients were admitted to a coronary 
care unit, where they remained for 48 to 72 h doting the 
acute phase of infarction. They were then transferred to a 
general ward and mobilized according to a defined scheme 
socb that omieots with uncomdicated infarction were dis- 
charged a&r 7 days. those withminor complications&r 10 
to 14 days and those with severe complications after 3 to 4 
weeks. 
One to 3 days before hoApiral discharge. all patients 
without primary exclusion criteria had an ambulatory 24 h 
ECG recording after discontinuation of all antiarrhythmic 
drugs for 224 h. Amiodarone was never used during the 
initial hospital stay. The 24 h ECG recordings et all three 
hospitals were made on a Dynegram model 5000 cassette 
recorder and centrally analyzed (playback at 60 times real 
time speed, lnstrttments for Cardiac Research, model W.MC 
Holler electrocardioscanner). The entire 24 h ECG was 
condensed beat by beat on fiberoptic p:~per. Arrhythmias 
detected by trained personnel were recorded at normal paoer 
speed and analyzed by a cardiologist according to the Lawn 
classification (12) and the number of ventricular premature 
beats per hour. If frequent multiform or repetitive ventricu- 
lar arrhythmias (Low class 3 or 4h) were present in 22 of 
24 h. patients were asked to consent to the study. They we 
then iandomized to one of the three treatment .&upson the 
basis of their hospital entry number and the randomization 
list. Standerd mdionuclide angiogrephy was performed to 
determine left ventricular ejection fraction et rest (13). 
Fdi~Mv-uo VI.,:~ were scheduled for all patients after 3. 6 
sod 12 months and included clinical examination, 24 h ECG 
recordings and drug level determinations if applicable. Pa- 
tients who were treated individually had additional visits as 
required. Patients no longer willing to adhere to the treat- 
ment regimen or to show up TOI follow-up eiaiwtion were 
contacted by telephone at the end of the year to obtain 
information about survival. 
The study protocol WBS approved by the Ethical Commit- 
tee of the University Hospital on Januery 29. 1981 and has 
previously been described in detail (14). 
Anliarrilyrhmic Trenwnenf Regimens 
Individualized autbrrhythmic lreatment (Group 1). While 
still in the hospital, patients in this group underwent oral 
drug testing with wntinuous ECC monitoring in the cm+ 
nary care unit or with repeated (usually six times) 30 min 
ECG trend scribing. Thereafter, drug therapy was monitored 
cm an outpatient b%s by frequent 24 h ECG recordings and 
serum drue. level measurements. In this t?mup, treatment 
was startea either with quinidine or mexiletine and dosage 
adjusted according to eficacy and side effects. Suppression 
of arrhythmias was considered effective if Lawn class b 
arrhythmias were eliminated and the number of ventricular 
premature beats was reduced by >SU%. In patients with 
ventricuiar tachvcardia. elimination of runs of three or more 
ventricular pre&tore beets and YW% reduction of couplets 
had to be achieved. Ifthe first drop, did not achieve this goal, 
the second drug WLS tested. In c&e of failure of both d&s. 
other aotierrhythmic drugs (ajmeline. disopyramide, Recain- 
id& propafenone or soralol) were tried. If none of these drug 
regimens was effective, amiodarone was given. 
Staadardiad anti&-rh@mii treatment with tow dose ami- 
odemite (Grow 2). Patients were given amiodarone (1,ooO 
mg orally for 5 days followed by a daily dose of 200 mglday). 
If symptomatic arrhythmias developed despite amiodarone 
adminishatian. antiarrhythmic therapy was changed and 
patients were considered to be treatment deviators. Patients 
were specifically questioned about side effects and under- 
went thyroid function tests, but no chest X-ray films or 
pulmonary function tests were routinely performed. 
Cootrol group without erdiarrhythnde therapy (Group 3). 
In this group, patients received no specific antierrhythmic 
treatment but were seen after 3,6 and I2 months when they 
underwent 24 h ECC monitoring. If symptoms due to 
arrhythmias developed, they were given antiarrhythmic 
drugs and were considered to be treatment deviators. 
Conwmitent treatmeal. Treatment other than admiois- 
tration of antiarrhythmic drop was not fixed and was left to 
tbe judgment of the responsible physician. Antithrombotic 
and beta-adrenergic blocking drugs es welt as coroeery 
artery bypass surgery were considered standard treatment of 
ischemic heart disease that could not be withheld for ethical 
reasonr. Such concomitant rreatment wa recorded as in an 
G:~servatlonal study. 
Analyses 
End point evaluation. Deaths were assessed without knowl- 
edge of the treatment group awgnment; evaluation was based 
on death certificates, physician and hospital records. au~p\y 
repons and tnfonnation obtained fmm relatives and witnews. 
Each death was asrimted to the treatment erou~) accordinr to 
the intention to &principle (15.16). 
Sudden dcorh was defined as death occurring without 
previous symptoms or within I h after the on&t oi new 
symptoms of heart disease (17). an unwitnecsed deaeuih wa\ 
icduded in this delnidon if Ihc pa&xl had been ubscrvcd w 
be free of symptoms ~24 h before he or rhe was found dead. 
Other csrdiuc deolh was defined as death GCCU~ ring >I h 
after the onset al cardiac symptoms. Cardiac arrest due to 
ventricular fibrillation with successful resusc~tatmn and OE- 
currence of sustained symptomatic or asymptomatic vcntric- 
ular tachycardia (210 consecutive beatc) were constdered 
secondary end points. Sudden death and sustained vattic- 
ular tachycardia or ventricular fibrillation were considered 
arrhythmic events. 
EmhWiott of treatmat etTWs. Effectiveness of the dif- 
ferent muiarrhythmic dlug regimens in suppressing ventncular 
ectopic astivity was assessed with respect to freqaency of 
ventricular memature beats and Lawn class. Fresuencv was 
defined by the average number of venrricular pre&mre~beatr 
per hour duing the entire 20 to 24 h ECG recording and the 
presence or absence of ?I0 ventricular premature beats. 
Slalii methods. Ott the basis of our initial expectn- 
Lions, a sample size of IO8 patients per group was estimated 
on the assumption of a I ycer mortality rate of 20% and a 
reduction in the mortality rate of ~50% by either drug 
rcguncn s n = 0.05. pvwuer = 80% ““e-tailed ,CS’,. All 
randomired patients were included in ihs mortfhty aw.tyses 
and all pauentr for whom data uere available wcri: mcluded 
,n rhe other analyses. All valoes :qxcsent rnezn wlucs - 1 
SD as an Index of dtspernon. Wdhtn treatme”, gioups. 
chxtge: i!! arrhy:hmias were aiae~d with repeated mea- 
WC\ analyw of variance and between group differences 
wt.? the cht-square test. The pmbabdity of survival and the 
occurrence ofarrhy~hmic events were calculated by Kaplan- 
Mcier acnxanal analysts (18.191. The Cox proportional haz- 
ardc rcgxc+n model (201 was used for adjustment of 
Fowblc baseline differences according to an intention to 
treat approach. All the reported p values are twwtxled. 
Calcuk~tmns were performed with the use of the Systat 
5LHtI\tICPI prcgrarn. 
Incidenrr and natural ECMM of persistent venlricular 
eclopic activity. During the study period. I.220 consecutive 
patients ~71 years of age were screened for persisting 
complex ventricular ectoptc actwtty before hospi!al dis- 
charge Of this cohon. 340 08%) had qualifymg asympto- 
matx arrhythmias: 28 patients (!3.2%1 did not consent to the 
<tudy. rewiring in a study group of 312 patients. Of these. 
C7r/, had repetitive forms of ventricular premature beatr 
(Low class 4). The average number of ventricular prema- 
ture beats per hour was 48 + 107. with 49% of patients 
having sID ventricular premature beats/h. 
Group 2 (low dose amiodarone) and I14 to Group 3 (control) 
(Table I). Tbrre were no significant differences among the 
three groups with regard to age, gender, history of coronary 
artery disease and hypertension, Q wave infarction, peak 
creating kinase values or left ventricular ejection fraction. 
The incidence and severity of ventricular ectopic activity 
were similar in all three groups, as was the number of 
patients with concomitant antithrombotic and beta-blocker 
treatment. 
E&x& of treatment on looaality. Tbe incidence of death 
in the three study grows is shown in Table 2. Overall. 30 
patients died (I year mortality rate 9.6%). Tbcre were three 
noncardiac deaths (two due to carcinoma and one to major 
mxardiac surgery). Twenty-two of the 27 cardisc deaths 
were sudden; P of these were unwitnessed. 
Figure I s.navs the probability of survive! for the threr 
treatment groups. TIx cumulative mortality rates at I: 
months were 13% in the control group. 10% in the individ- 
uatly treated group and 5% in amiodarone-treated patients, 
indicating that in this study amiodarone reduced tbe totat 
mortality rate by 61% from that in the control group (p c: 
0.05). This diierettce also held true after adjustments in the 
CQ?. model for the minor diierences in baseline variables, 
such as age, previous myoeardial infarrrion and left vearic- 
alar ejection fraction. individual treatment reduced the 
mortality rate by 24% from t&t in the control group. but this 
di5erenc.e wrts not significant. A&r exclusion of noncardiac 
deaths, the mortality rate was still 55% less for amiodarane- 
treated patientsandZl%les~ for individually treated patients 
@we I. Prcbability of I2 month survival in the three treatment 
grows of patients with asymptomatic complex ventricular arrhyth- 
mias after mywardii infarction. 
T&k 3. Comparison of Survivors and Patients Who Died From 
Cardiac Death 
than for the control patients. Patients with cardiac death 
d&red significantly from sutvivors only by a lower left 
ventricular ejection fraction (Table 3). 
EBeds of tmlmeot on u&ythmk evett!s. During the I 
year follow-up period, eight patients had symptomatic ven- 
tricular tachycwdia or fibrillation and were rucccsstidly 
resuscitated. In five additional patients, sustained asympto- 
matic ventricular tachycardia was recorded on routine 24 h 
ECG recordings (Table 4). Sudden death and sustained 
ventricular tachycardia or fibrillation warred significantly 
less o&en in patients treated with amicdamne than in the 
control group (5 of 98 versus 19 of 114. nduction of 66%. 
p < 0.01). whereas the etlbct on arrbythmic events in 
individually treated patients was less marked (10 of 100. 
reduction of 40%. p = NS). Likewise, the probability of a 
clinical course free of symptomatic wrbythmic events for the 
three groups showed a significant bettdit only for amic- 
darone-treated patients (p < 0.025) (Fig. 2). 
Lawn class z-3 arrhythmias. the main the&eutie targei for 
this study, were signbicantly reduced by bath treatment 
regimens at each follow-up study (Table 5). A comparison of 
the number of ventricular premature beats per hour in tbe 
three groups at the 3, 6 and I2 month studies showed no 
significant differences; however, there was a significant 
treatment effect over time with amiodamne, which w.xz less 
pronounced and not significant for individually treated pa- 
tients. 
Table 4. Incidence of Anhythmic Events in the Three 
Study Oroupn 
Flgwr 1. Robability of an arrbythmic evenl-free course during the 
I year follow-up period in ,he three trtaunen, wup3 of pa,xn,r 
wi,hasymp,oma,iccomplen v lri~ulararrhy,hm~aaf,ermyocard~al 
infarclion. Anhythmic even& are sudden dearh. vemriculx fib+ 
lalion and symptomatic suslained ‘~enrricular uchgcardxa. 
Anttarrbythmie Irealmmt given. Gf IW drug trials in ,he 
98 individually treated patients, 70 were performed with 
qtinidine and 79 with mexiletine in different doses. Respec- 
tively, these dlugs proved to be effective in 3% and 32%. 
ineffective in 47% and 42% and were discominued because 
of side effects in 23% and 26%. ThiTtY-three patients in 
whom both treatments failed were given pmpafenonr tn = 
r7), Recainide (,, = 14). sot&l (n = 5). disopyramide In = 4). 
prajmaline (n = 4) or drug combinations (some patients 
recetved up 10 seven diEwent drugs). In addirion. nine 
patients crossed over 10 amicdarone aRer an average of 3.3 
previous drug trials. Palients in lhis group who survived ,he 
I yea, study paiod had an average of 2.1 drug trials. 7.4 
?4 h ECF recordiqr and 3.5 drug level dererminations. In 
the xmiodaronr-treated group. four patienls received an 
mcreased dose. whereas five had their dose reduced ,o 101) 
mglday. 
Treatment de&x&x, and tdereoce. In Table 6 the inci- 
dence cl side effecects. lack of compliance and change of 
treatmen, are compared ior all rhree study gmoups. Twenty- 
two patients changed their study medicarion: II patients in 
the conlml group experienced symplomatic aatxylhmias and 
were given antiarrhythmic medication. In nine individually 
treated pa,ien,s (Group I). no treatment proved to be e&c- 
five or wilhoo, side etTec,s and they received amiodamne. In 
two patients from the amiodamne treatment group (Group 
2). the trearmen, age”, was changed 10 so,alol because of 
side effecls. 
Sixty-nine patients (22%) disconlinued the study prema- 
turely because they wilhdrew their cooper&on (n = 42) or 
T&k 5. E&c, of Anfiarrhylhmic Trearmen, on Lawn Arrhylhmld Glade and Frequency of 
Vcn,ricular Ecropic Ac,ivi,y 
Lawn gr& ,!a p,icn,s 
whh Low” @. 1 I, 
1716 
experienced side e5ec;s (n = 27). Fourteen individually 
treated patients and 13 amiodamne-treated patients tina!ly 
stopped their medication because of side effects. Reasons for 
discontinuation of amiodarone were ocular side ebcts (n = 
3). hyperthyroidism or hypothyroidism (n = 4). bradycardia 
or dizziness (n = 2). dermatologic effects (n = Z), gastric 
symptoms (n = t) and hair loss (n = I). No pulmonary and 
no irreversible toxicity were observed. Altogether. 59 pa- 
tients (59%) tn the individually treated group (Group I) 
finished the study with their assigned treatment, compared 
with 69 patients (75%) in the amiodarone group (Group 2) 
and 93 patients (82%) in the cnntrol group (Group 3). 
Discussion 
Amiodarone lhtrapy of pmtiufaretlau ventrfeufar arrhylh- 
mitt. This study showed a significant reduction in mortality 
by amiodarone in a high risk group of patients with arymg 
tomatic persistent complex ventricular arrhythmias after 
myocardial infarction. The prevalence of ventricular prema- 
ture beats 2 weeks after infarction was similar to that 
recently described in the placebo group of the Beta-Blocker 
Heart Attack Trial (BHAT) (22). Lnwn class r3 arrhythmias 
were selected as target arrhythmias for the present study in 
1980, long before the greater predictive power of higher 
density and repetitive forms of ventricular premature bents 
was realized. The same is true for the definition of arrhyth- 
mia suppression. The observed I year mortality rate of 13% 
in the control group confhms the selection of a high risk 
group of patients for this study: it is much higher than the 
control group mortdity rnte observed in the Cardiac Ar- 
rhythmia Suppression Trial (CAST) (IO) control patients. 
fatluanee of nntiarrhythmic therapy nn mwtality afler 
mynawtial iufarction. Although ventricular ectopic activity 
is assacia:ed with ?n increased mortality rate in srrvivors of 
acute myocardial infarction and although this effe :: seems to 
be ittdependent of other risk factors, there has been no 
evidence to date that treatment of arrhythmias cm reduce 
this risk (6-9). In retrospective s!udies (9,22’. oatieats 
responding to antiarrhythmic therapy had a si::n8tcantly 
better clinical course than nonrespnuders. indicating that 
drug response might be a marker of a more benign undedy- 
ing disease. The results of the present study with the 
individualized antiarrhythmic treatment approach showed a 
suppression in ventricular ectopic activity without a signift- 
cant reduction in mortality. However, no ewess mortality 
was observed in our patients treated with class 1 antiarrhyth- 
mic drugs in contrast to what has been reported recenrly in 
CAST (lo) for class Ic drugs. Fkcainide. which depresses 
conductbn more than other class I antiarrhythmie agents 
(23). was used infrequently in our study and encainide was 
not used at all. Conversely, amiodarone significantly re- 
duced not only the total mortality rate, but also all arrhyth- 
mic events. 
Possible meebantsms uf n&n of smkdamm. Because 
arrhythmia suppression with amiodarone was similar to that 
with individualized therapy, other mechanisms for mortality 
reduction need to be discussed. The antifibrillatory et&t of 
amiodarone (23) seems to be the most likely beneficial 
mechanism. acting by slowing of ventricular tachycardia. 
Other mechanisms eem mnre speculative; amiodarone has 
antiischemic (24.25) and antiadrenergic (26) effects that 
might be contributory in patients after myoeardial infarction, 
as in the case of bera-blocking drugs. The special phamta- 
cokinetics of amiodarone with its long half-We might be 
particularly impnrtaut for a sustained e5ect. Sudden death 
occurred more frequently during the loading phase of this 
treatment arm (three of four sudden deaths within the first 2 
manths ofamiodarnne therapy), whereas it occurred later in 
the individually treated and cotttrol patients. One could 
speculate that with a more aggressive loading dose at the 
beginning oftreatment, the result could have been improved 
even further. In addition, amiodarone exerts virtuatly no 
negative inotmpic effects during long-term administration 
(25). Finally, the minimal proarrhythmic properties of ami- 
odarone are in contrast to those of other anliatrhythmic 
drugs such as Aecainide and encainide (27). 
lndividualiwd antirrhylhmfe treatmeut sppfoaeh. An in- 
dividualized antiarrhythmic treatment approach was chosen 
for Group I to find an aptimal drug treatment regimen for 
each patient. Because of the large spontaneous vatiability in 
arrhythmia nceurrence, this demanded not only aeute drug 
testing, but continuous adjustments of therapy throughout 
the follow-up period. Only 39 patients were given just one 
autiarrhythmic drug, whereas 35 patients received at least 
three different drugs in various dosages. Despite the possi- 
bility of avoiding side effects by changing treatment, 14% of 
the patients in this group finally discontinued all antiarrhyth- 
mic therapy for this reason. Interpretation of the results in 
this group is difficult because arrhythmia control was rela. 
lively pow and these patients bad many more follow-np 
visits for treatment management. In addition, 50% of pa- 
tients who died in this group did so after protocol deviation 
(Table 6). Aitogether, individualized antiarrhythmic therapy 
proved to be cumbersome and costly and did not reduce 
mortality signitieantly. 
Spenific us@s of the study design. This study was 
performed prospectively and randomization to the three 
treatment groups was balanced. However, because of its 
principal design, the study could not be performed in a 
double-blind fashion. Therefore, the main emphasis of this 
study was placed on mortality (28). Because there was a 
significant mortality reduction with one treatment regimen, 
this result is vu80 despite the lack of a double-blind design. 
To cnrrect for minor di5erences in baseline characteristics 
that could have influenced survival, the Cox model was used 
and confirmed the significant difference in mortality between 
the amiodarone and control groups. Beta-blocking drugs 
were not withheld in the mesenl studv. althoueh thev arc 
known to influence sur&al after &ocardiai mf&ion 
(29-32). On one hand, it was iudeed cthxallv imoowble to ” _ 
withhold beta-blocker therapy, and on the oiher. trzatment 
with propranolol has own shown not to alter the ielation 
between ventricular ectopic activity and mortality 133). 
Finally. amiodarone is a drug with ootcntially severe \ldc 
effects (34-36). Therefore. the low- dose re&nen of ?W 
mp/day was used. Careful patient monitoring (36) chowed a 
much lower incidence of sihe effects than that reported wth 
higher dosages (35.36). 
Rekvance and implications of the reulls. Despite the 
relatively small number of patients e rolle:! in the study. ths 
overall differences in mortality and arrhythmic events were 
large enough to reach statistical significance. The obwvcd 
reduction in mortality was of such a magnitude that it is 
clinically relevanl even if only cardiac deaths were consid- 
ered. This inlerpretstion is supported by the highly GJ ,IS- 
cant di6erences in symptomatic and all arrhythmlc evwi~ 
between amicdarone-treated and conlrol patients. In addi- 
tion, similar differences in favor ofamiodarone were noted m 
the smaller Canadian Amiwlaronc After Myocardial Infarc- 
lion pilot study (37) as well as in patients with hypertrophic 
cardiomyopathy (38). Nevertheless, these findings will re- 
quire confirmation in more extensive studies under way in 
Europe and the United States. 
In view of the large number of palients who experience 
sudden cardiac death (9.39). improving survival in these 
patients is ofgreat clinical importance. Our findings indicate 
that a simple treatment regimen with low dose amiodarone 
may reduce mortality in the high risk subgroup of patients 
with asymptomatic complex venbicula: ectopic activily per- 
sisting after myocardial infarction. 
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